Schizophrenia
Conditions
Interventions
ultra-high-risk of schizophrenia experimental group:Take Shizhenanshen granules and aripiprazole placebo
ultra-high-risk of schizophrenia control group:Take aripiprazole and Shizhen'anshen placebo
first episode schizophrenia experimental group:Take Shizhenanshen granules and aripiprazole
first episode schizophrenia control group:Take aripiprazole and Shizhen'anshen placebo
Sponsors
Beijing Anding Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: 1. meet the criteria for the study of schizophrenia, high-risk groups standards or first episode schizophrenia; 2. Aged between 18 and 30 years (including 18 and 30); 3. Sign the informed consent and be able to comply with the research scheme; 4. Understand the follow-up questionnaire survey; 5. Meet the criteria of the standard of traditional Chinese medicine syndromes of hyperactivity of fire due to deficiency of kidney yin (hallucinations, delusions, weird thinking, thinking lax, looseness of thought, stunned and speechless, automatic speaking and laughing, solitude, soreness and weakness of waist and knees, dry mouth, constipation, red tongue, Thin tongue coating with teeth marks, fine rapid stringlike pulse)
Exclusion criteria
Exclusion criteria: 1. Have severe suicidal tendencies; 2. Be in a depressive episode; 3. With serious or unstable heart, liver, kidney, endocrine, blood and other medical diseases; 4. Be treated with antipsychotic medications within 4 weeks; 5. Unattended; 6. Compared to baseline, the reduction rate of ultra-high-risk of schizophrenia structured interview scale screening score is more than 25%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptoms assessment;assessment of cognition function;assessment of adverse reaction; | — |
Countries
China
Contacts
Public ContactJia Hongxiao
Beijing Anding Hospital, Capital Medical University
Outcome results
None listed